All In Biotech

Drug Trial Radar · NCT06038916

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Phase Ib/II Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Dec 9, 2023

Primary completion

Mar 20, 2025

Study completion Apr 27, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

  • STSA-1002 Injection PlaceboDrug

    Intravenous infusion

  • STSA-1002 InjectionDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical remission timeTime frame: Baseline to Day28

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University

    Chongqing, Chongqing Municipality, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Second Hospital of Hebei Medical University City:Shijiazhuang

    Shijiazhuang, Hebei, China

  • Huaihe Hospital of Henan University

    Kaifeng, Henan, China

  • Kaifeng Central Hospital

    Kaifeng, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical College

    Xingxiang, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Wuhan Jinyintan Hospital

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China

  • Zhongda Hospital affiliated to Southeast University

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China

  • Zibo Municipal Hospital

    Zibo, Shandong, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Chengdu Medical College

    Chengdu, Sichuan, China

  • Chengdu Fifth People's Hospital

    Chengdu, Sichuan, China

  • Hangzhou Red Cross Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.